• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer

    12/12/23 8:01:00 AM ET
    $INTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $INTS alert in real time by email

    Mr. Talamo brings over 25 years of experience leading financial strategies to support both publicly traded and privately held development and commercial stage biopharmaceutical companies

    SHELTON, Conn., Dec. 12, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (NASDAQ:INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced the appointment of Joseph Talamo as Chief Financial Officer (CFO). Mr. Talamo will be working at Intensity headquarters as a full time employee. An accomplished executive with more than 25 years of leadership experience in the biotechnology space, Mr. Talamo most recently served as Senior Vice President and Chief Financial Officer of HiberCell. Mr. John Wesolowski will remain as the Company's Principal Accounting Officer and Controller. 

    Logo (PRNewsfoto/Intensity Therapeutics Inc.)

    "I am delighted to welcome Joe to Intensity, his wealth of experience as a biotechnology executive and track record of success in leading financial operations will prove invaluable as we transition to a late-stage clinical company," said Lewis H. Bender, President and Chief Executive Officer of Intensity. "I look forward to leveraging his versatile experience as we pursue our goal of treating solid tumors with our lead asset INT230-6."

    As CFO, Mr. Talamo will develop and implement Intensity's financial strategies and lead financial reporting, finance corporate development, strategy and investor relations efforts while supporting the Company's overall business goals. Most recently, Mr. Talamo served as the CFO of HiberCell, building the financial and accounting function, and overseeing the evaluation of financing and strategic initiatives. Prior to HiberCell, Mr. Talamo spent ten years at Caladrius Biosciences, a clinical-stage biotech company dedicated to the development of cellular therapies, most recently serving as CFO. Before his tenure at Caladrius Biosciences, Mr. Talamo served as Vice President and Corporate Controller for OSI Pharmaceuticals. Mr. Talamo holds an MBA in Finance and a BBA in Accounting from Hofstra University. He also is a CPA registered in New York.

    "I am thrilled to join Intensity at this pivotal time in the Company's evolution as its lead candidate INT230-6 is anticipated to enter a Phase 3 clinical trial," said Mr. Talamo. "Intensity's novel intratumoral delivery technology is at the forefront of innovation. I look forward to working closely with the team to advance Intensity's financial strategy and further its mission to improve the lives of patients who are impacted by the debilitating effects of cancer."

    About INT230-6

    INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform. The drug is composed of two proven, potent anti-cancer agents, cisplatin and vinblastine, and a penetration enhancer molecule (SHAO) that helps disperse potent cytotoxic drugs throughout tumors for diffusion into cancer cells. These agents remain in the tumor resulting in a favorable safety profile. In addition to local disease control, direct killing of the tumor by INT230-6 releases a bolus of neoantigens specific to the patient's malignancy, leading to engagement of the immune system and systemic anti-tumor effects. Importantly, these effects are mediated without immunosuppression that so often occurs with systemic chemotherapy.

    About Intensity Therapeutics

    Intensity Therapeutics is a late-stage biotechnology company that applies novel engineered chemistry to turn "cold" tumors "hot" by enabling its aqueous cytotoxic-containing drug product, INT230-6, to mix and saturate the dense, high-fat pressurized environment of the tumor. As a result of the saturation, Intensity's clinical trials have demonstrated the ability of INT230-6 to kill tumors and elicit an adaptive immune response within days of injection, representing a truly novel approach to cancer cell death that holds the potential to shift the treatment paradigm and turn many deadly cancers into chronic diseases. For more information about the Company, including publications, papers and posters about its novel approach to cancer therapeutics, visit www.intensitytherapeutics.com. INT230-6 has completed enrollment of over 200 patients in two phase 2 and phase 1 dose escalation clinical trials (NCT03058289 and NCT04781725) with various advanced solid tumors; IT-01 in metastatic disease, and IT-02 the INVINCIBLE study, in presurgical breast cancer. The Company partnered with Merck Sharpe & Dohme (Merck) to evaluate the combination of INT230-6, Intensity's lead product candidate, and KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 (programmed death receptor-1) therapy, in patients with advanced pancreatic, colon, squamous cell and bile duct malignancies. The Company also partnered with Bristol-Myers Squibb to evaluate the combination of INT230-6 with Bristol-Myers Squibb's anti-CTLA-4 antibody, ipilimumab, in patients with advanced liver, breast and sarcoma cancers. Intensity managed the individual combination arms separately with each respective partner via a joint development committee. The Company also executed agreements with the Ottawa Hospital Research Institute (OHRI) and the Ontario Institute of Cancer Research (OICR) to study INT230-6 in the INVINCIBLE study, a randomized controlled neoadjuvant phase 2 study in women with early-stage breast cancer.

    Forward-Looking Statements

    Certain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the expected future plans, development activities, projected milestones, business activities or results. We have based these forward-looking statements on our current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, include: the risk that the anticipated milestones may be delayed or not occur or be changed, as well as other risks described in the section entitled "Risk Factors" in the Company's SEC filings, which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

    Investor Relations Contact:

    Argot Partners

    Jonathan Nugent

    [email protected]

    Media Contact:

    Argot Partners

    David Rosen

    david.rosen@argotpartners.com

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/intensity-therapeutics-appoints-joseph-talamo-cpa-as-chief-financial-officer-302011949.html

    SOURCE Intensity Therapeutics Inc.

    Get the next $INTS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INTS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $INTS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

      SHELTON, Conn., May 29, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces that the Company will be presenting a Trials in Progress poster outlining its Phase 3 INVINCIBLE-3 clinical trial of INT230-6 for the treatment of metastatic soft tissue sarcomas. The poster will be shown at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting held at McCormick Place in Chicago May 30-June 5, 2025.

      5/29/25 8:00:00 AM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon

      SHELTON, Conn., May 28, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (NASDAQ:INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral investigational cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces a collaboration to educate patients with early stage breast cancer about potential new therapeutic options with model, author, executive producer, speaker, and breast cancer survivor Christine Handy. The film, Hello Beautiful, an adaptation of Ms. Handy's award-winning novel Walk Beside Me, recently won the Golden Palm Award at

      5/28/25 8:00:00 AM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Eight Swiss sites are activated in the INVINCIBLE-4 Study, and several patients have been treatedEuropean Medicines Agency Authorization to initiate INVINCIBLE-4-Study in FranceSHELTON, Conn., May 13, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces first quarter 2025 financial results and provides a corporate update.

      5/13/25 4:06:00 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INTS
    Financials

    Live finance-specific insights

    See more
    • Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

      32 sites are currently contracted in the INVINCIBLE-3 Study, and 25 patients have been screenedEight Swiss sites are activated in the INVINCIBLE-4 Study, and several patients have been screenedFinal sarcoma data from our first metastatic study and our INVINCIBLE-3 Study design was presented at the annual Connective Tissue Oncology Society Meeting in November 2024Final data from our first neoadjuvant breast cancer study and our INVINCIBLE-4 Study design was presented at the annual San Antonio Breast Cancer Society Meeting in December 2024SHELTON, Conn., March 13, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology

      3/13/25 4:07:00 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

      First patient dosed in randomized, Phase 2 study in presurgical triple negative breast cancer SHELTON, Conn., Nov. 13, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces third quarter 2024 financial results and provides a corporate update. Corporate Update INVINCIBLE-3 Study: a Phase 3 open-label, rand

      11/13/24 4:06:00 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INTS
    Leadership Updates

    Live Leadership Updates

    See more
    • Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors

      SHELTON, Conn., May 15, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces the appointment of Thomas Dubin, J.D., MPH, to the Intensity Board of Directors, effective May 14, 2024. Mr. Dubin will serve as a member of the Audit Committee of the Board. In connection with Mr. Dubin's appointment, the size of the Board was increased from four directors to five. Of these five directors, four are independent pursuant to Nas

      5/15/24 8:01:00 AM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer

      Mr. Talamo brings over 25 years of experience leading financial strategies to support both publicly traded and privately held development and commercial stage biopharmaceutical companies SHELTON, Conn., Dec. 12, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (NASDAQ:INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced the appointment of Joseph Talamo as Chief Financial Officer (CFO). Mr. Talamo will be working at Intensity headquarters as a full time employee. An accomplished executive with more than

      12/12/23 8:01:00 AM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Intensity Therapeutics Inc.

      SC 13G - INTENSITY THERAPEUTICS, INC. (0001567264) (Subject)

      6/7/24 5:29:04 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Intensity Therapeutics Inc.

      SC 13G - INTENSITY THERAPEUTICS, INC. (0001567264) (Subject)

      2/13/24 4:01:30 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INTS
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Intensity Therapeutics Inc.

      DEFA14A - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

      6/2/25 4:02:41 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Intensity Therapeutics Inc.

      DEF 14A - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

      6/2/25 4:01:48 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intensity Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

      5/20/25 4:05:38 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Principal Accounting Officer Wesolowski John M

      4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

      5/6/25 4:21:05 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Dubin Thomas I H

      4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

      5/6/25 4:11:54 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Donovan Daniel

      4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

      5/6/25 4:11:09 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care